The Hill: The FDA approves a breakthrough treatment for the world’s deadliest infectious disease — now what?
Eric P. Goosby, the U.N. secretary general’s special envoy on TB and the MacArthur Foundation Chair in Global Health Sciences at the University of California, San Francisco

“…[T]he U.S. Food and Drug Administration’s approval of a new drug to tackle treatment-resistant TB has been hailed as a monumental breakthrough. … The question now becomes: How do we make sure that the people who need this new treatment — and other TB prevention and treatment efforts — have access to them? From my experience as the former U.S. Global AIDS Coordinator and, currently, as the U.N. Special Envoy on TB, the answer is for all parties is to work together to increase financing and strengthen coordination targeted where the need is the greatest. This shared responsibility model means that impacted countries must step up their game and provide more financial resources to tackle TB. … [I]t will take a shared responsibility from all in the global health community, as well as significant movement on UHC, to ensure treatments get to those who need them most” (9/23).